Course Information

6th Annual UCHMC Research Symposium

UCLA Meyer & Renee Luskin Conference Center
Los Angeles, California

October 19, 2021

*Please note that the course syllabus will be available online only to registered attendees.
A password link will be sent prior to the course.

Syllabus for Conference Registrants

The University of California Hematologic Malignancies Consortium (UCHMC) is a collaboration across the 5 University of California Cancer Centers to conduct multicenter investigator initiated clinical trials in a more efficient and effective manner. The annual UCHMC research symposium is formatted to highlight the research being conducted across the UC system.

The 6th Annual UCHMC Research Symposium will include discussions on opportunities for collaboration across the UC system, translating recent laboratory discoveries into new therapies, application of novel therapies in hematologic malignancies, and ongoing clinical trials currently being conducted by the UC Hematologic Malignancies Consortium.

The research symposium will provide attendees with information regarding current research in the field and application of novel therapies allowing those in attendance to better serve their patient population.

Physicians, mid-level practitioners, clinical trials staff, fellows, students, basic and translational scientists are encouraged to attend and participate. We are hopeful that this meeting will help (1) patients receive effective treatments, (2) help investigators develop innovative clinical trials and (3) spur new translational laboratory and clinical investigations within the UC system.


*Note: To ensure course material is received before the course begins, early registration is advised. Online registration will close at 11:59 PM on Monday, October 11th.

Enrollment after online registration has closed:

  • Option 1: Please call (310) 794 – 2620 between 8:00 AM – 5:00 PM (Pacific Standard Time) by Friday, October 15th.
  • Option 2: After 5:00 PM on Friday, October 15th, please enroll onsite. No registration will be accepted via phone.

Course Fees

  • Academic Participants: $0
    *If you are a member of the University of California Hematologic Malignancies Consortium (UCHMC) or part of an approved UCHMC affiliated site, please do not register online. Please email Farzam Hariri at to confirm your eligibility and provide your registration information.
  • Industry and Other Partcipants: $500

Enroll Online

To enroll, click here.


No refunds will be granted for this course. If, for any reason, the course must be cancelled, discontinued, or rescheduled by the Office of Continuing Medical Education, a full refund will be provided.

Course Director

Gary Schiller, MD, FACP
Director, Hematological Malignancy and Hematopoietic
Cell Transplant Program
David Geffen School of Medicine at UCLA


Haifaa Abdulhaq, MD – UCSF Fresno
Shagun Arora, MD – UCSF
Caitlin Costello, MD – UCSD
Wendy Cozen, MD – UC Irvine
Sven De Vos, MD – UCLA
Herbert Eradat, MD – UCLA
Deepa Jeyakumar, MD – UC Irvine
Caspian Oliai, MD – UCLA
Tamer Othman, MD – UC Davis
Nick Pannunzio, PhD – UC Irvine
Aaron Rosenberg, MD – UC Davis
Christopher Seet, MD, PhD – UCLA
Joseph Tuscano, MD – UC Davis
Matthew Wieduwilt, MD, PhD – Chair, UCHMC

Oral Abstract Speakers

Kwan-Keat Ang, MD – UC Davis
Daria Gaut, MD – UCLA
Eli Soyfer, MD – UC Irvine

Planning Committee Faculty

Haifaa Abdulhaq, MD – UCSF Fresno
Lloyd Damon, MD – UCSF
Deepa Jeyakumar, MD – UC Irvine
Aaron Logan, MD, PhD – UCSF
Erin Reid, MD – UC San Diego
Joseph Tuscano, MD – UC Davis
Matthew Wieduwilt, MD, PhD – Chair, UCHMC

Tuesday, October 19, 2021

7:00 am Registration and Breakfast
7:55 am Welcome
8:00 am - 9:30 am
Hematologic Malignancies Research Session 1
8:00 am Investigational Cellular Therapy for Relapsed Lymphoma
Sven DeVos, MD, PhD (UC Los Angeles)
8:30 am Multiple Myeloma Epidemiology
Wendy Cozen, DO, MPH (UC Irvine)
9:00 am The Impact of COVID on Heme Malignancies
Shagun Arora, MD (UC San Francisco)
9:30 am Break
10:00 am - 11:00 am
Hematologic Malignancies Research Session 2
10:00 am Engineered T cell Therapies from Pluripotent Stem Cells
Christopher Seet, MD, PhD (UC Los Angeles)
10:30 am CNS Lymphoma
Haifaa Abdulhaq, MD (UCSF Fresno)
11:00 am Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Secondary Central Nervous System Lymphoma
Daria Gaut, MD (UCLA)
11:15 am Decreased Chimeric Antigen Receptor T-Cell Efficacy with Severe or Prolonged Post-Infusion Cytopenias
Daria Gaut, MD (UCLA)
11:30 am Utilization of Non-Invasive Sample Sources for Identification of Somatic and Germline Mutations in Hematologic Malignancies and Clonal Hematopoiesis
Eli M. Soyfer, MD (UCI)
11:45 pm Efficacy and Safety of Bortezomib in Once Weekly vs. Twice Weekly Dosing in the Treatment of Multiple Myeloma
Kwan-Keat Ang, MD (UCD)
12:00 pm Acalabrutinib Maintenance Following Cellular Therapy for Large B-cell Lymphoma Patients at High Risk for Relapse
Daria Gaut, MD (UCLA)
12:15 pm Tagraxofusp-based Therapy as Treatment for Measurable Residual Disease of Acute Myelogenous Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation
Daria Gaut, MD (UCLA)
12:40 pm Lunch
2:00 pm - 3:30 pm
UCHMC Trial Talks
2:00 pm UCHMC1502
Aaron Rosenberg, MD (UCD)
2:10 pm UCHMC1504
Matthew Wieduwilt, MD, PhD (OU)
2:20 pm UCHMC1809
Caitlin Costello, MD (UCSD)
2:30 pm UCHMC1812 and UCHMC2124
Caspian Oliai, MD (UCLA)
2:40 pm UCHMC1913
Deepa Jeyakumar, MD (UCI)
2:50 pm UCHMC1914
Matthew Wieduwilt, MD, PhD (OU)
3:00 pm UCHMC1916
Joseph Tuscano, MD (UCD)
3:10 pm UCHMC2018
Joseph Tuscano, MD (UCD)
3:20 pm UCHMC2020
Joseph Tuscano, MD (UCD)
3:30 pm Break
4:00 pm - 5:30 pm
Hematologic Malignancies Research
4:00 pm Mechanistic Insight into the Etiology of B Cell Malignancies
Nick Pannunzio, PhD (UC Irvine)
4:30 pm DEL Project First-Line Treatment with R-CHOP vs Dose-Adjusted R-EPOCH for Double-Expressor Lymphoma
Tamer Othman, MD, (UC Davis)
5:00 pm Novel therapies for CLL
Herbert Eradat, MD (UC Los Angeles)
5:30 pm Adjourn

At the completion of this program, participants should be better able to:

  • Gain an understanding novel treatments and regimens in clinical trials and how basic research discoveries are being translated into clinical trials
  • Gain a better understanding of best practice in the management of hematologic malignancies
  • Become familiar with targeted and immunotherapeutic approaches for the treatment of hematologic malignancies

The Office of Continuing Medical Education, David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Office of Continuing Medical Education, David Geffen School of Medicine at UCLA designates this live activity for a maximum of 7 AMA PRA Category 1 Credits TM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

The California State Board of Registered Nursing accepts courses approved by the AMA for category 1 credit as meeting the continuing education requirements for license renewal. Nurses from states other than California should inquire with their local State Board for specific continuing education policies.

The FDA has issued a concept paper which classifies commercial support of scientific and educational programs as promotional unless it can be affirmed that the program is "truly independent" and free of commercial influence. In addition to independence, the FDA requires that nonpromotional, commercially supported education be objective, balanced, and scientifically rigorous. The policy further states that all potential conflicts of interest of the CME staff and faculty be fully disclosed to the program's participants. In addition, Accreditation Council for Continuing Medical Education policy mandates that the provider adequately manages all identified potential conflicts of interest prior to the program. We at UCLA fully endorse the letter and spirit of these concepts.


UCLA Luskin Conference Center
425 Westwood Plaza
Los Angeles, CA 90095
(855) 522-8252


A block of limited rooms has been reserved at the on-site hotel of the Luskin Conference Center at a special rate of $239.00 single or double occupancy per night. All reservations must be guaranteed with a major credit card and accompanied by a first night room deposit. Confirmation of reservations made after September 30, 2021 is subject to availability.

Conference Code: LG2110UCHA

To reserve online, please click HERE.

To reserve by phone, call the conference center directly at (855) 522-8252 and request the group rate for the UCHMC UC Hematologic Malignancies Consortium.


From the 405 freeway, exit Wilshire Blvd. East toward Westwood. Turn left on Westwood Blvd., travel past Charles E. Young Dr. South and turn left on Parking Structure 8 Driveway. Proceed up the ramp to the rooftop level to park. Pay-by-plate machines are available on the rooftop level. Credit cards are accepted. A pedestrian walkway/bridge connects Parking Structure 8 to the Luskin Conference Center. Take the east stairs down one level (from Level 4 to Level 3) and cross over Strathmore Place. The entrance will be on your right-hand side.

Please click here for most current parking rates.

Additional Information

For more information about the University of California Hematologic Malignancies Consortium (UCHMC), please visit

Oral Abstract Submission

To submit an oral abstract for consideration, please email Farzam Hariri at Instructions and other information about the oral abstract guidelines are also available at